Angelica M Gutierrez Barrera1, Tamer M Fouad2,3, Juhee Song4, Rachel Webster1,5, Nisreen Elsayegh1, Anita L Wood2, Atakan Demir1,6, Jennifer K Litton1, Naoto T Ueno1,2, Banu K Arun1. 1. Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. MD Anderson Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Medical Oncology, The National Cancer Institute, Cairo University, Cairo, Egypt. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Clinical Cancer Genetics Program, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Medical Oncology, Umraniye Research and Training Hospital, Umraniye, Istanbul, Turkey.
Abstract
BACKGROUND: Inflammatory breast cancer (IBC) often affects women at a relatively young age. To the authors' knowledge, the rate of BRCA variants among patients with IBC is not known. To determine the association between BRCA status and IBC, the authors evaluated its rate and compared the clinicopathologic characteristics of patients with IBC with those of patients with other breast cancers (non-IBC). METHODS: Patients who presented at the study institution's cancer genetics program and who underwent BRCA genetic testing were included in the current study. The authors compared clinicopathologic data between patients with IBC and those with non-IBC using propensity score matching to identify predictors. RESULTS: A total of 1789 patients who underwent BRCA genetic testing (1684 with non-IBC and 105 with IBC) were included. BRCA pathogenic variants were found in 27.3% of patients with non-IBC and 18.1% of patients with IBC (P = .0384). After propensity score matching, there were no significant differences noted between patients with IBC and those with non-IBC, including the rate of BRCA pathogenic variants (P = .5485). However, a subgroup analysis of the 479 patients with BRCA pathogenic variants demonstrated that patients with IBC (19 patients) were diagnosed at significantly younger ages compared with patients with non-IBC (P = .0244). CONCLUSIONS: There was no clear association observed between BRCA pathogenic variants and IBC. However, among patients who tested positive for BRCA pathogenic variants, those with IBC were younger at the time of diagnosis compared with those with non-IBC breast cancers. These results confirm that genetic testing is important for patients with IBC who meet the current clinical criteria for genetic testing in breast cancer. Cancer 2018;124:466-74.
BACKGROUND:Inflammatory breast cancer (IBC) often affects women at a relatively young age. To the authors' knowledge, the rate of BRCA variants among patients with IBC is not known. To determine the association between BRCA status and IBC, the authors evaluated its rate and compared the clinicopathologic characteristics of patients with IBC with those of patients with other breast cancers (non-IBC). METHODS:Patients who presented at the study institution's cancer genetics program and who underwent BRCA genetic testing were included in the current study. The authors compared clinicopathologic data between patients with IBC and those with non-IBC using propensity score matching to identify predictors. RESULTS: A total of 1789 patients who underwent BRCA genetic testing (1684 with non-IBC and 105 with IBC) were included. BRCA pathogenic variants were found in 27.3% of patients with non-IBC and 18.1% of patients with IBC (P = .0384). After propensity score matching, there were no significant differences noted between patients with IBC and those with non-IBC, including the rate of BRCA pathogenic variants (P = .5485). However, a subgroup analysis of the 479 patients with BRCA pathogenic variants demonstrated that patients with IBC (19 patients) were diagnosed at significantly younger ages compared with patients with non-IBC (P = .0244). CONCLUSIONS: There was no clear association observed between BRCA pathogenic variants and IBC. However, among patients who tested positive for BRCA pathogenic variants, those with IBC were younger at the time of diagnosis compared with those with non-IBC breast cancers. These results confirm that genetic testing is important for patients with IBC who meet the current clinical criteria for genetic testing in breast cancer. Cancer 2018;124:466-74.
Authors: Soley Bayraktar; Angelica M Gutierrez-Barrera; Diane Liu; Tunc Tasbas; Ugur Akar; Jennifer K Litton; E Lin; Constance T Albarracin; Funda Meric-Bernstam; Ana M Gonzalez-Angulo; Gabriel N Hortobagyi; Banu K Arun Journal: Breast Cancer Res Treat Date: 2011-08-10 Impact factor: 4.872
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver Journal: Breast Cancer Res Treat Date: 2012-06-26 Impact factor: 4.872
Authors: H Masuda; T M Brewer; D D Liu; T Iwamoto; Y Shen; L Hsu; J S Willey; A M Gonzalez-Angulo; M Chavez-MacGregor; T M Fouad; W A Woodward; J M Reuben; V Valero; R H Alvarez; G N Hortobagyi; N T Ueno Journal: Ann Oncol Date: 2013-12-18 Impact factor: 32.976
Authors: Tamer M Fouad; Angelica M Gutierrez Barrera; James M Reuben; Anthony Lucci; Wendy A Woodward; Michael C Stauder; Bora Lim; Sarah M DeSnyder; Banu Arun; Babiera Gildy; Vicente Valero; Gabriel N Hortobagyi; Naoto T Ueno Journal: Lancet Oncol Date: 2017-04 Impact factor: 41.316
Authors: Tamer M Fouad; Takahiro Kogawa; Diane D Liu; Yu Shen; Hiroko Masuda; Randa El-Zein; Wendy A Woodward; Mariana Chavez-MacGregor; Ricardo H Alvarez; Banu Arun; Anthony Lucci; Savitri Krishnamurthy; Gildy Babiera; Thomas A Buchholz; Vicente Valero; Naoto T Ueno Journal: Breast Cancer Res Treat Date: 2015-05-29 Impact factor: 4.872
Authors: Catherine Schairer; Yan Li; Peter Frawley; Barry I Graubard; Robert D Wellman; Diana S M Buist; Karla Kerlikowske; Tracy L Onega; William F Anderson; Diana L Miglioretti Journal: J Natl Cancer Inst Date: 2013-09-18 Impact factor: 13.506
Authors: David J H Shih; Mei-Kuang Chen; Jun Yin; Daniel J McGrail; Hui Dai; Rongbin Wei; Jing Zhang; Wenjin Jim Zheng; Kim-Anh Do; Liuqing Yang; Mien-Chie Hung; Shiaw-Yih Lin Journal: Am J Cancer Res Date: 2022-01-15 Impact factor: 6.166